IV PERSANTINE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IV PERSANTINE is an injectable small-molecule drug developed by Boehringer Ingelheim, approved in 1990. The generic name and specific indications are not disclosed in available data, but it is administered intravenously as a diagnostic or therapeutic agent. Exact mechanism of action requires additional clinical context.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling transition planning and consolidation of team resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IV PERSANTINE currently has zero linked job openings, reflecting its late-lifecycle status and consolidation phase. Career opportunities are limited and primarily defensive in nature, focused on managed decline and generics transition rather than growth initiatives.
Brand ManagerMedical Science Liaison
Worked on IV PERSANTINE at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.